Transaction #13849 · Form 4 · 0001104659-25-117451
Altimmune, Inc. · Stock award · Restricted Stock Units
Altimmune, Inc. · Transacted December 1, 2025 · Filed December 1, 2025
What does this filing report?
An SEC Form 4 filing for Altimmune, Inc. records a stock award involving Restricted Stock Units on December 1, 2025. The reported quantity was 633,700. The filing date is December 1, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Altimmune, Inc.
- Company CIK
- 0001326190
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 633,700
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 633,700
- Ownership description
- Not reported
- SEC acceptance time
- Dec 1, 2025, 8:38 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Durso Jerome Benedict ↗
CEO-elect · Director
CIK 0001698665
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock, par value $0.0001
- Underlying quantity
- 633,700
- Conversion / exercise price
- Not reported
- Exercise date
- Not reported
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on December 1, 2026, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
- F2
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
- F3
- The RSUs become vested over four (4) years with 25% of the shares vesting December 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Remarks
Mr. Durso has been appointed President and Chief Executive Officer of the Company effective January 1, 2026.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.